By: Denise Myshko From: onclive.com Investigators are evaluating the addition of nivolumab to standard neoadjuvant therapy in patients with high-risk, estrogen-receptor–positive/ HER2-negative breast cancer to determine whether the PD-1 immune checkpoint inhibitor can improve recurrence rates. Investigators are evaluating the addition of nivolumab (Opdivo) to standard neoadjuvant therapy in patients with high-risk, estrogen-receptor (ER)–positive/ HER2-negative breast cancer to determine whether …
Promising Combinations Surpass Standard of Care in Advanced Renal Cell Carcinoma
By: Nichole Tucker From: targetedonc.com Multiple studies have shown combinations of checkpoint inhibitors and chemotherapy prolong progression-free survival (PFS) and improve overall survival (OS) in patients with RCC. In the CheckMate 214 study of nivolumab (Opdivo) plus ipilimumab (Yervoy) versus sunitinib (NCT02231749) in advanced disease patients, those who received the combination achieved higher OS rates at 18 months(75% vs 60%) …
Doctors Excited By Results Of New Immunotherapy Cancer Treatment
By: Dr. Maria Simbra From: pittsburgh.cbslocal.com No chemotherapy, No radiation. There’s a new way to treat cancer that doesn’t involve either. It’s working for patients and even doctors are excited about it. Joe Milcarek had no symptoms of lung cancer. Doctors discovered it on scans he had as part of participation in a lung study. “They found a tumor about …
Terminal cancer patients could be saved by ‘exciting’ new treatment
By: Sophie Borland From: dailymail.co.uk Thousands of terminally-ill cancer patients could go into remission by being given two breakthrough drugs at the same time, research shows. Trials unveiled at the world’s largest cancer conference have shown that a new technique of offering two types of immunotherapy at once– not just one – more than doubles the numbers of patients who …
Head and neck cancer drug ‘game changer’
By: Michelle Roberts From: bbc.com A new type of cancer drug that wakes up the patient’s own immune system to fight tumours could be a game changer for tackling aggressive head and neck cancers, say experts. Trial results coming out of a US cancer conference suggest the treatment works better than standard chemotherapy. Nivolumab significantly improved the survival odds of …
HUNDREDS of cancer victims given hope as drug ‘cure’ is fast-tracked
By: Lucy Johnston From: express.co.uk A REVOLUTIONARY cancer drug expected to save hundreds of lives a year has been deemed so effective that the Government has bypassed red tape to make it available on the NHS immediately. From tomorrow patients with advanced kidney cancer will be able to access the landmark drug nivolumab.The treatment has not yet been given a …
UK Green-Lights New Drug For Advanced Skin Cancer
By: Katrina Pascual From: techtimes.com Pharmaceutical company Bristol-Myers Squibb has received a nod from United Kingdom’s health cost regulators for the use of its drug Opdivo (nivolumab) in skin cancer cases. The company previously failed to obtain the same recommendation from the National Institute for Health and Care Excellence (NICE) for Opdivo as lung tumor treatment. Following the approval, the …
Breakthrough drug sets body on cancer warpath means new future for patients
By: Lucy Johnson From: express.co.uk A DRUG which unleashes the body’s immune system against tumours has been hailed as a “new dawn in cancer treatment” Experts are amazed at the success of the trials, which one oncologist said were “almost too good to be true”. The results are so promising that a recent trial of the therapy in patients with …
Bristol-Myers, Ono Sue Merck Over Cancer-Drug Patent
By: Peter Loftus From: wsj.com Bristol-Myers Squibb Co. BMY -0.83% and partner Ono Pharmaceutical Co. 4528.TO -0.43% have sued Merck & Co. MRK -0.92% , alleging that its new cancer drug violates their patent for a method of harnessing the body’s immune system to fight cancer. Bristol and Ono filed suit in federal court in Delaware on Thursday, the same …